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In Brief Hu et al. analyzed the contribution of MLL2's methyltransferase and CXXC domain in the trimethylation of H3K4 in mouse ES cells and find that while it trimethylates H3K4 at both bivalent gene promoters and non-TSS elements, it regulates transcription at a limited number of genes including those required for PGC specification.
INTRODUCTION
Histone H3K4me3 is an evolutionarily conserved chromatin mark from yeast to mammals and is associated with diverse chromatin-based processes, such as chromatin remodeling, transcriptional initiation, histone acetylation, and DNA recombination (Li et al., 2006; Matthews et al., 2007; Vermeulen et al., 2010) . In budding yeast, H3K4 methylation is deposited by Set1/COMPASS (complex of proteins associated with Set1) (Krogan et al., 2002; Miller et al., 2001; Roguev et al., 2001; Schneider et al., 2005; Shilatifard, 2012) . Drosophila has three Set1-related H3K4 methyltransferases, dSet1, Trithorax (Trx), and Trithorax-related (Trr), each of which forms a COMPASSlike complex (Mohan et al., 2011; Shilatifard, 2012) . Mammals have two close relatives for each of the three H3K4 methyltransferases identified in Drosophila, resulting in a total of six COMPASS-like complexes: Set1a and Set1b; Mll1 and Mll2; and Mll3 and Mll4 Shilatifard, 2012) . Functional diversity within the COMPASS family in metazoans includes deposition of distinct methylation states of H3K4 and targeting distinct genomic regions. The Set1 proteins within COMPASS mediate the bulk of promoter H3K4me3 through crosstalk with the H2B monoubiquitination machinery (Mohan et al., 2011; Wu et al., 2008) . Mll1 is required for H3K4me3 at the promoters of a subset of genes in mouse embryonic fibroblasts (MEFs) (Wang et al., 2009 ), while Mll2 is responsible for implementation of H3K4me3 at bivalently marked gene promoters in mouse embryonic stem cells (mESC) (Hu et al., 2013b) . Recently, the Drosophila ortholog of Mll1 and Mll2 was shown to implement H3K4me2 at Polycomb response elements (Rickels et al., 2016) . In contrast, the enhancer mark H3K4me1 is largely implemented by Trr in Drosophila and Mll3 and Mll4 in mammals (Herz et al., 2012 (Herz et al., , 2014 Hu et al., 2013a; Morgan and Shilatifard, 2015) .
From yeast to humans, a direct functional role for H3K4 methylation in transcription remains unclear. Set1/COMPASS is the only H3K4 methyltansferase in yeast and its deletion affects all three states of H3K4 methylation (Schneider et al., 2005; Shilatifard, 2012) . Nevertheless, there is no widespread transcriptional alteration in the absence of Set1 in budding yeast (Miller et al., 2001) . Likewise, in mammalian cells, the loss of H3K4me3 at promoters has minimal effects on steady-state and regulated transcriptional induction in mESC (Clouaire (legend continued on next page) Hu et al., 2013b) . Therefore, the role of H3K4 methylation in regulating transcription and embryonic development remains elusive. In this study, we uncover an essential role for the catalytic activity of Mll2/COMPASS in H3K4 methylation in the regulation of a limited number of genes, including at enhancers and promoters of genes encoding regulators of PGC specification.
RESULTS

Mll2/COMPASS Occupies Both Promoters and Non-TSS Regulatory Elements in mESC
Histone H3K4me3 accumulates at promoter-proximal regions of active genes but can also be found with H3K27me3 at the lowly transcribed ''bivalent'' genes in ES cells (Azuara et al., 2006; Bernstein et al., 2006; Santos-Rosa et al., 2002) . We previously demonstrated that the H3K4me3 at bivalent promoters in ES cells is implemented by the Mll2 branch of the COMPASS family (Hu et al., 2013b) . To gain a broader understanding of the role of Mll2/COMPASS in transcriptional regulation during development, we generated antibodies recognizing two different epitopes in the C-terminal portion of Mll2 (ab CT1 and more C-terminal ab CT2) ( Figure S1A ). We first confirmed the specificity of the two antibodies in the detection of endogenous Mll2 protein by immunoblotting whole-cell extracts from mESC in which Mll2 was depleted by RNAi ( Figure S1B ). We further validated the two antibodies with immunoprecipitation and found that components of Mll2/COMPASS were co-immunoprecipitated with Mll2 (Figures S1C and S1D). We identified Mll2 targets by ChIP-seq with each antibody ( Figures 1A and S1E) . A total of 19,822 binding regions (peaks) were identified with ab CT2 Mll2, among which 70%, 14%, and 16% of peaks are localized to promoters, gene bodies, and intergenic regions, respectively ( Figure 1A ). The high percentage of Mll2 occupancy at promoters was consistent with its activity at bivalent genes in mESC (Hu et al., 2013b) . Mll2 peaks localized within some gene bodies or at intergenic regions (non-TSS) demonstrated a lower occupancy than sites of Mll2 occupancy overlapping transcription start sites (TSS) ( Figure 1B ). Similar results were observed when performing ChIP-seq with ab CT1 (Figures S1E and S1F). Inspection of non-TSS Mll2 peaks near H3f3a and Foxj2 loci reveals that they are co-occupied with the active enhancer marks p300, H3K4me1, and H3K27ac (Figure 1C) . Non-TSS Mll2 peaks can be associated with p300, H3K4me1, H3K27ac, and H3K27me3 ( Figures 1D and S1G) . More of the non-TSS Mll2-associated regions are enriched for the active enhancer marks of p300, H3K4me1, and H3K27ac, than for H3K27me3, a mark of poised enhancers (Rada-Iglesias et al., 2011) (Figures 1D, 1E , S1G, and S1H).
Approximately 39% of non-TSS Mll2-associated elements (2,465 out of 6,418) share marks with active enhancers (Figure 1F) , half of which are further marked with H3K4me3 (Figure 1F) . Similar percentages of co-occurrence of H3K4me3 with marks of active enhancers were observed with Mll2 ab CT1 ( Figure S1I ) or with H3K4me3 ChIP-seq datasets generated in different mESC lines and by distinct laboratories (Clouaire et al., 2014; Denissov et al., 2014; Mikkelsen et al., 2007) (Figure S1J ). Gene expression analysis revealed that genes closest to non-TSS Mll2 sites had an overall higher expression level than all genes, consistent with them being enhancers ( Figure 1G ). Genes nearest non-TSS Mll2 sites with H3K27ac had further increased expression, consistent with these being active enhancers ( Figure 1G ). However, the co-occurrence of H3K4me3 with these putative active enhancers was not significantly predictive of higher expression than H3K27ac alone ( Figure 1G , group II versus group I), suggesting that for a majority of these putative enhancers, Mll2-dependent H3K4me3 functions redundantly with H3K27ac and is not associated with driving increased expression in the ES cell state.
Mll2
Catalyzes H3K4 Methylation at Non-TSS Sites As Mll2 functions as a methyltransferase for H3K4 and associates with non-TSS Mll2-associated sites enriched for H3K4me3, we reasoned that Mll2 may be the enzyme directly responsible for implementation of H3K4me3 at the non-TSS Mll2-associated sites. To explore this hypothesis, we employed H3K4me3 ChIP-seq in mESC infected with lentiviral shRNA against GFP and Mll2, respectively. Efficient knockdown of Mll2 has previously been described (Hu et al., 2013b ) and confirmed at the protein level ( Figure S1B ). Mll2 depletion resulted in nearly complete loss of its occupancy around H3f3a and Foxj2, indicating the specificity of this antibody for ChIPseq ( Figure 1H ). Histone H3K4me3 occupancy at enhancers of H3f3a and Foxj2 was similarly reduced after Mll2 depletion (C) Genome browser tracks of Mll2, p300, H3K4me1, and H3K27ac at putative enhancers. (D and E) Binary enrichment profiles (D) and binding percentages (E) for Mll2, p300, H3K4me1, H3K27ac, H3K27me3, and H3K4me3 ± 5 kb regions centered at 6,418 high-confidence non-TSS Mll2 peaks. Enrichment determined by p < 1e-8 and FDR < 0.05. (F) Percentage of 6,418 high-confidence non-TSS Mll2-bound regions that are enriched for indicated histone marks. Group I regions have enrichment for p300, H3K4me1, and H3K27ac, while Group II regions exhibit occupancy of p300, H3K4me1, H3K27ac, and H3K4me3. (G) Gene expression analysis of RNA-seq data in mESC for all genes, nearest genes of all 6,418 high-confidence non-TSS Mll2 peaks, or Mll2-associated Group I and Group II regions. Boxes display the 25%-75% ranked genes with the median indicated as an intersection. p value determined by Wilcoxon rank-sum test. (H) ChIP-seq profiles for H3K4me3 and Mll2 at putative enhancer regions from (C) in mESC infected with lentiviral shRNAs targeting Mll2 (shMll2) or control (shGFP). (I) ChIP-qPCR validation of changes at putative enhancers indicated in (H). ChIP signals were calculated as percentages of input and then normalized to that obtained from shGFP cells and presented in the log2 scale. Error bars indicate the standard deviation from two technical replicates, representative of three biological replicates. (J) Heatmap of Mll2 and H3K4me3 ChIP-seq occupancy ± 5 kb at the 6,418 non-TSS Mll2 peaks in Mll2 and control knockdown cells (left). H3K4me3 log2 fold change after Mll2 depletion is shown 5 kb flanking 6,418 non-TSS Mll2 peaks (middle). H3K27ac occupancy for the same regions is shown (right). The heatmap is rank ordered from 6,418 sites with highest to lowest occupancy of Mll2 in mESC. (K) Boxplot representation of ChIP-seq occupancy for Mll2 and H3K4me3 at 6,418 non-TSS Mll2 targets. p values determined by Wilcoxon rank-sum test. See also Figure S1 . (legend continued on next page) ( Figure 1H ). In contrast, H3K4me3 levels at the promoters of H3f3a and Foxj2 were unaffected ( Figures 1H and 1I ).
To further investigate the role of Mll2 in H3K4me3 deposition at non-TSS Mll2-associated sites, we performed global analysis of Mll2 and H3K4me3 in shGFP and shMll2-treated cells. Mll2 depletion resulted in broad reduction of H3K4me3 levels and Mll2 occupancy at non-TSS Mll2-associated sites targets (Figures 1J and 1K) . To rule out the possibility that H3K4me3 at non-TSS sites was a crosslinking artifact due to enhancer-promoter interactions, ChIP-seq with native MNase-digested chromatin was performed ( Figure S1K ).
Cxxc1/Cfp1, a subunit found in Set1A and Set1B/COMPASS (Shilatifard 2012) , is required for targeting Set1A and Set1B to promoters of active genes and establishing H3K4me3 in mESC (Clouaire et al., 2012) . However, at non-TSS Mll2-associated sites, H3K4me3 occupancy remained unchanged in the absence of Cxxc1 ( Figure S1L ), further indicating the specific requirement for Mll2/COMPASS in H3K4me3 deposition at these regions. Direct regulation of H3K4me3 was further validated by determining Mll2 and H3K4me3 occupancies at non-TSS Mll2 bound regions identified by the CT1 Mll2 antibody ( Figure S1M ). Together, our data established a requirement of Mll2/COMPASS for H3K4me3 deposition at a subset of non-TSS sites in mESC.
Ectopically Expressed Mll2 Depends on Its CXXC Domain for Recruitment to Chromatin
Menin associates with the Mll1 and Mll2 COMPASS-like complexes and is required for targeting MLL1 fusion proteins to genomic loci associated with leukemic transformation (Yokoyama et al., 2005) . We performed ChIP-seq for Menin in mESC and observed that Menin co-occurs with Mll2 at putative enhancers close to H3f3a and Foxj2 ( Figure S2A ). Despite cooccurring at many loci ( Figure S2B ), depletion of Menin by shRNA had no delectable effect on Mll2 recruitment in mESC ( Figures S2C and S2D ), suggesting that Menin-dependent recruitment to chromatin could be cellular context dependent.
To identify the molecular mechanisms underlying Mll2 targeting to chromatin, we used CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats) technology (Cong et al., 2013) , to generate Mll2 knockout (Mll2KO) mESC, which could be further used in rescue experiments (Figure 2A ). Western blot analysis of a representative mESC clone demonstrated a complete loss of Mll2 protein in Mll2KO mESC ( Figure 2B ). Consistent with the shRNA-mediated Mll2 knockdown studies, Mll2 knockout had no major effect on bulk levels of H3K4 methylation in mESC ( Figure 2B ). We first tested the requirement for the CXXC domain of Mll2 for its targeting to chromatin, since the homologous domain in Mll1 can bind unmethylated CpG-containing DNA and plays an essential role in the recruitment of MLL1 fusion proteins to HOXA9 in leukemia cells (Ayton et al., 2004; Cierpicki et al., 2010) . Although most promoters in mammals are characterized by the presence of CpG islands (Guenther et al., 2007) , about half of mammalian CpG islands are found in intragenic and intergenic regions (Illingworth et al., 2010) .
We reintroduced wild-type, CXXC domain-deficient (DCXXC), or the catalytically mutant (Y2604A) versions of Halo-tagged human MLL2 ( Figure 2C ) into Mll2KO mESC. Different rescue constructs were expressed to similar levels as endogenous Mll2 ( Figure 2D ) and all of the proteins could assemble into COMPASS-like complexes (Figures 2E and S2E) . While the wild-type MLL2 construct was able to fully rescue H3K4me3 defect at non-TSS Mll2-associated sites, the CXXC and Y2604A mutants could not . Although the Y2604A and wild-type Halo human MLL2 proteins were properly recruited to Mll2-associated regions, the recruitment of the CXXC mutant was impaired ( Figures 2I, 2J , and S2G). In line with a role for the CXXC domain in recruiting Mll2 to chromatin, the non-TSS Mll2 sites overlap CpG-rich regions (Figure 2G and 2I) .
CRISPR-Mediated Genome Editing of Endogenous Mll2's CXXC and Catalytic Domains
We used CRISPR-mediated homologous recombination to mutate six of the eight conserved cysteine residues to alanine to abolish CXXC function of the endogenous Mll2, and tyrosine 2602 (corresponding to tyrosine 2604 in human MLL2) to alanine to generate catalytically deficient Mll2, respectively (Figures 3A, 3B, and S3A-S3F). Western blotting in the targeted mESC clones demonstrated that the amino acid substitutions have no observable impact on Mll2 protein levels ( Figure 3C ). ChIP-seq for H3K4me3 in parental, Mll2 knockout, and two independent clones each for the CXXC domain and catalytic mutants, demonstrated a requirement for Mll2's CXXC domain and catalytic activity for non-TSS H3K4me3 ( Figures 3D, 3E , S3G, and S3H). ChIP-seq for Mll2 demonstrated that the catalytic mutant, but not the CXXC mutants, was properly recruited to non-TSS Mll2-associated sites and bivalent promoters (Figures 3F, 3G, and S3I) . Taken together, these findings establish an essential role for the CXXC domain and the methyltransferase activity of Mll2 in ES cells for chromatin targeting and H3K4me3 deposition at non-TSS Mll2-associated sites.
Mll2 Is Required for Expression of Regulators of Primordial Germ Cell Specification during Differentiation
Mll2 is essential for embryonic development but is not required to maintain the pluripotent state (Glaser et al., 2006; Lubitz et al., 2007) . To explore Mll2's role during early development, we conducted RNA-seq analysis in parental and Mll2KO mESC and during their differentiation ( Figure S4A ). In agreement with a dispensable role for Mll2 in self-renewal, RNA-seq analysis in Mll2KO mESC demonstrated no significant changes in the expression of pluripotency genes, such as Oct4 and Klf4 (Figure S4B) . However, gene expression analysis in Mll2KO mESC identified 286 genes that were downregulated and 327 genes that were upregulated ( Figure 4A ). Functional annotation of downregulated genes revealed enrichment for different classes of genes including those involved in germ cell development and gamete generation (Castrillon et al., 2000; Fujiwara et al., 1994; Noce et al., 2001; Ohinata et al., 2005; West et al., 2009; Yamaji et al., 2008 ) ( Figure 4B ; Table S1 ). In contrast, genes upregulated in Mll2KO cells were enriched in categories such as brain and pancreas development, and metabolic process (Figure 4B) . Consistent with our RNA-seq analysis suggesting a role for Mll2 in gamete generation, Mll2 conditional germline knockouts exhibit sterility in both males and females (AndreuVieyra et al., 2010; Glaser et al., 2006) . Prdm1, Prdm14, Lin28b, and Ddx4 encode regulators for the specification of primordial germ cells (PGC) from pluripotent mESC state (Ohinata et al., 2005; West et al., 2009; Yamaji et al., 2008 ) that were among the downregulated genes in the Mll2KO cells ( Figure 4C ; Table S2 ). To examine potential Mll2 functions during differentiation specifically in PGC specification, we generated embryoid bodies (EBs) from wild-type and Mll2KO mESC and performed RNAseq ( Figure 4D ). Mll2 transcripts were initially upregulated and then downregulated during the course of EB formation and this was also reflected at the protein level as shown by immunoblotting of whole cellular extracts of EBs ( Figures 4D, 4E , S4C, and S4D). Compared to ES cells, many more genes were misregulated later in differentiation in EB stages ( Figure 4F ). However, we observed that the expression of some of the regulators of PGC specification are reduced from day 0 to day 9 of Mll2KO EB formation, demonstrating Mlll2's role for transcriptional activation of germ cell determinants during development ( Figure 4G ; Table S2 ). We note that the dependency on Mll2 is most obvious during the differentiation studies as the dependency on Mll2 in the ES cell state can vary with growth conditions.
Although loss of Mll2 does not affect self-renewal of mESC grown under serum + LIF condition, Mll2KO mES cells exhibit faster mRNA depletion for Nanog and Klf4 during differentiation ( Figure S4E ). Supporting the accelerated differentiation of the Mll2KO mESC, we observed that many markers of endoderm, mesoderm, and ectoderm have significantly higher expression at different days of Mll2KO EBs than in wild-type EBs (Figures  S4F-S4H ; Table S2 ). Taken together, these studies suggest a role for Mll2 in PGC induction and the proper orchestration of differentiation for PGC and other lineages.
Both the CXXC Domain and the H3K4 Methyltransferase Activity of Mll2 Are Required for PGC Induction from mESC To better understand the requirement of Mll2 for expression of genes involved in PGC specification during differentiation, we compared the gene expression profile in parental, Mll2 knockout, CXXC mutant, and catalytically deficient Mll2 mESC ( Figure S5A ). Hierarchical clustering of differentially expressed genes across these cell lines reveal that expression changes in CXXC and catalytically deficient mutant Mll2 cells are similar to Mll2KO cells ( Figure 5A ). The expression of PGC determinants such as Prdm14 and Prdm1 were decreased in mESC lacking either the DNA binding or the methyltransferase activity of endogenous Mll2 (Figures 5B and S5B) .
To further determine the role of Mll2 in PGC specification during mESC differentiation, we differentiated parental, Mll2 knockout, CXXC, and catalytically deficient mutant Mll2 mESC into EBs ( Figure 5C ). Similar to Mll2KO EBs, EBs derived from CXXC and catalytically deficient mutant Mll2 mESC were heterogeneous in morphology and display dark regions in the center of their EBs, although the extent was less severe as compared to Mll2KO EBs ( Figure 5C ). We analyzed RNA-seq data from EBs differentiated from parental, Mll2KO, CXXC, and catalytically deficient Mll2 mutant mESC and observed reduced expression of Prdm1 and Prdm14 in day 6 EBs derived from Mll2_mCXXC, Mll2_Y2602A, and Mlll2 KO EBs, indicating an essential role for the CXXC domain and the full enzymatic activity for Mll2-dependent PGC formation ( Figures 5D, S5C , and S5D).
As EBs represent spontaneous differentiation of ES cells and the number of PGC in EBs was potentially low, we decided to test the function and respective mechanisms (CXXC domain unsuccessfully amplified with primers P1 and P2 in two targeted ES cell clones due to the large Neo cassette but can be amplified after FLP-mediated excision of Neo, with the PCR product migrating slower than the wild-type product due to a remaining FRT site. Figure 1J . See also Figure S3 . (legend continued on next page) and full methyltransferase activity) of Mll2 in PGC induction in a more controlled model of PGC differentiation system. mESC of parental, Mll2KO, Mll2_mCXXC, and Mll2_Y2602A grown under N2B27+2i+LIF conditions were first induced to differentiate into Epiblast-like cells (EpiLC) followed by addition of multiple cytokines to dictate PGCLC specification ( Figure 5E , top). As seen in EBs, expression of PGC determinants Prdm1, Prdm14, and Dppa3 was considerably decreased while markers for endoderm and ectoderm were upregulated in PGCLC aggregates derived from Mll2KO, Mll2_mCXXC, and Mll2_Y2602A mESC, further supporting the essential role for Mll2 and its CXXC domain and catalytic activity in PGC induction ( Figure 5E , bottom). As expected, the number of PGCLCs derived from Mll2KO, Mll2_mCXXC, and Mll2_Y2602A cells was decreased 4-fold as demonstrated by flow cytometric analysis of PGC markers (Hayashi and Saitou, 2013) ( Figure 5F ). Collectively, our findings support a role for Mll2, its ability to bind DNA, and its methyltransferase activity in PGC specification during ES cell differentiation.
Regulation of Enhancer Activity by Mll2/COMPASS during PGC Specification
Among the 6,418 non-TSS Mll2-associated sites, 58% of them were enriched for enhancer marks ( Figure 1F ). We observed that genes closest to non-TSS Mll2-associated sites had higher expression than all genes; however, loss of Mll2 had no general effect on the expression of the nearest genes in ES cells (Figure S6A) . Of the 4,684 genes nearest non-TSS Mll2-associated sites, only 43 genes were significantly downregulated by Mll2 loss ( Figure S6B ), including genes encoding PGC regulators. The low number of downregulated genes nearest non-TSS sites is consistent with the observation from Figure 1G that the presence of H3K4me3 at putative active enhancers conferred no general advantage on gene expression when compared to other active enhancers. Together, these findings indicate that loss of H3K4me3 at non-TSS sites does not have a general instructive role in transcriptional activation, but instead depends on other, yet identified chromatin contexts. However, we cannot rule out that the minimal effect of loss of Mll2 and H3K4me3 on nearby gene expression was the result of a low level of H3K4me3 implemented by other enzymes being sufficient for gene activation, as we rarely observed a complete lack of H3K4me3 at non-TSS Mll2-associated sites upon Mll2 deletion. We identified putative enhancer regions in mESC that required Mll2 for their H3K4me3 near PGC determinants such as Prdm14 and Prdm1 ( Figure 6A ). To determine whether they function as true enhancers for regulation of Prdm1 and Prdm14 transcription, we deleted these genomic elements by CRISPR/Cas9 (Figures 6B , 6C, and S6C). As expected, deletion of these elements led to decreased expression of Prdm1 and Prdm14, indicating that they are bona fide enhancers for Prdm1 and Prdm14 (Figures 6D and S6D ). In addition to H3K4me3 loss in Mll2KO cells, enhancers of Prdm1 and Prdm14 exhibited reduced levels of p300 and H3K27ac, two marks associated with active enhancers, while the general enhancer mark, H3K4me1, was largely unaffected ( Figure S6E) . However, global analysis of H3K4me1 at 6,418 non-TSS Mll2-associated sites demonstrated a very weak, but significant increase after Mll2 loss ( Figures S6F and S6G ). This could reflect some degree of competition between Mll2/COMPASS and other COMPASS family members such as the monomethylases MLL3 and MLL4 (Hu et al., 2013a) .
One mechanism underlying enhancer action is the physical association with targeted gene promoters (Dekker et al., 2002; Ong and Corces, 2011) . To explore whether there are physical contacts between enhancers and promoters of PGC determinants, we performed circularized chromosome capture (4C) coupled with high-throughput sequencing in mESC using genomic regions near the promoters of Prdm1 and Prdm14 as viewpoints. Significant 4C-seq signal from both viewpoints was observed at enhancer regions with Mll2-dependent H3K4me3, suggesting that Mll2-regulated enhancers indeed loop into close proximity with promoters of PGC determinant genes ( Figure 6E ).
To determine whether Mll2, its CXXC domain or its catalytic activity play a direct role in the regulation of cis-regulatory elements of Prdm1 and Prdm14, their enhancers and promoters were individually cloned into luciferase reporter constructs and co-transfected with Halo-tagged human MLL2 or its mutant derivatives in HEK293 cells. We observed that the activity of enhancers and promoters of Prdm1 and Prdm14 can be stimulated by expression of wild-type MLL2. This MLL2 activity was abolished by either deletion of its CXXC domain or mutation of the SET domain, indicating that the stimulation of enhancer and promoter activity by MLL2 is dependent on the DNA binding activity of its CXXC domain and the catalytic activity of its SET domain ( Figure 6F ).
The requirement of Mll2's methyltransferase activity and DNA binding activity for Prdm1 and Prdm14 enhancer function prompted us to test whether establishment of enhancer-promoter interaction requires Mll2 or its methyltransferase activity. We performed 4C with the Prdm14 promoter as viewpoint in wild-type, KO, and CXXC and catalytic Mll2 mutant mESC. We found that Mll2 deletion, inhibition of its chromatin recruitment, or mutation of its catalytic domain has no observable impact on the interaction between the enhancers and the promoter of Prdm14 ( Figure S6H ). However, further studies are needed to (B) Gene Ontology (GO) functional analysis for differentially expressed genes as determined by Metascape . Each node represents a functional term and its size is proportional to the number of genes falling into that term, with the color representing the cluster identity. Terms with a similarity score >0 
(legend continued on next page)
better understand the role of H3K4 methylation in the regulation of enhancer and promoter communication at other loci. To investigate a role of Mll2 and Mll2-dependent enhancers in PGC specification, we differentiated parental, Mll2KO, Prdm1, and Prdm14 enhancer-deleted mESC into PGCLC in vitro followed by flow cytometric analysis of PGCLC markers. As seen with Mll2KO mESC, Prdm14 enhancer deletion also leads to inefficient specification of PGCLC ( Figure 6G ). However, we did not observe a defect in PGCLC differentiation with the deletion of the distal Prdm1 enhancer (En1, data not shown), suggesting that the second enhancer (En2) residing within the gene body of Prdm1 may compensate for the loss of function of En1 during differentiation. In summary, our results demonstrate a molecular mechanism in which the recruitment of Mll2/COMPASS onto CpG island embedded enhancers establishes H3K4me3 and activates factors essential for PGC specification (Figure 7 ).
DISCUSSION
Here, we have demonstrated that Mll2/COMPASS occupies some promoters and non-TSS regulatory elements and implements H3K4me3 at these loci. We found that Mll2 is required for the expression of several genes including the master regulators required for primordial germ cell specification during ES cell differentiation. The DNA binding activity of the CXXC domain and the catalytic activity are indispensable for Mll2's function in the regulation of PGC specification during differentiation, suggesting that the recruitment of the catalytic activity of Mll2/ COMPASS to these loci is central for its specific transcriptional regulatory properties. Given that Mll2/COMPASS can methylate thousands of promoters and non-TSS regulatory elements, but only a subset of genes require Mll2/COMPASS and its catalytic activity in H3K4 trimethylation for the regulation of gene expression, our findings suggest that not all H3K4-methylated sites are functionally equal. In line with an active regulatory role for H3K4me3 in PGC gene expression, deletion of Kdm5b, a H3K4me3 demethylase, leads to a global increase of H3K4me3 and a failure to silence the expression of PGC genes (Schmitz et al., 2011) . Together, these findings point to an essential role of H3K4me3 in PGC establishment during embryonic differentiation. Since we observe that Mll2 is required for H3K4me3 at both promoters and enhancers of PGC genes, determining the degree to which H3K4me3 changes at promoters or enhancers of these genes is an important area of future investigation.
Nanog is a core pluripotency factor required for both the pluripotent mESC and the unipotent PGCs. Ectopic expression of Nanog in EpiLCs is sufficient to induce PGCLCs formation without addition of exogenous cytokines (Murakami et al., 2016) . Mechanistic studies revealed that Nanog associates with the enhancers of Prdm1 and Prdm14 and is required for their activation during PGC induction (Murakami et al., 2016) . As we noticed an accelerated reduction in Nanog expression in Mll2KO mESC during differentiation ( Figure S4E ), lowered expression of Nanog may partially account for the failure to fully activate Prdm1 and Prdm14 in the absence of Mll2.
CpG islands are found at promoters of bivalent genes targeted by Mll2 in mESC (Bernstein et al., 2006; Hu et al., 2013b) and artificial integration of synthetic CpG islands into the mESC genome can create novel bivalent domains that are independent of Cxxc1-containing Set1A/Set1B/COMPASS-like complexes (Wachter et al., 2014) . We observed that non-TSS regulatory elements targeted by Mll2 in mESC also show enrichment for CpG dinucleotides ( Figures 2G and 2I ). Mll2 harbors a CXXC domain, which can bind specifically to nonmethylated CpG (Voo et al., 2000) and this domain is essential for targeting Mll2 to these regions.
Since both Mll1 and the Cxxc1 subunit of Set1A-and Set1B/ COMPASS have CXXC domains, it is unclear how Mll2 is preferentially recruited for H3K4me3 at non-TSS Mll2-associated sites in ES cells. More than half of non-TSS Mll2-associated sites are enriched for the enhancer mark of H3K4me1. We previously demonstrated that Mll3/Mll4/COMPASS-like complexes are recruited to enhancers for H3K4 monomethylation (Herz et al., 2012; Hu et al., 2013a) . Determining how enhancers specifically choose Mll2 for their H3K4 trimethylation and Mll3/Mll4 for their H3K4 monomethylation will be important for understanding functional differences in different cis-regulatory elements and how they function to regulate pluripotency and development.
The molecular basis for H3K4me3-dependent transcriptional activation of genes during differentiation is currently unknown. Histone H3K4me3 has been previously reported to participate in many biological processes including nucleosome remodeling, transcription initiation, VDJ rearrangement, pre-mRNA splicing, and DNA damage response through binding to distinct effector proteins (Li et al., 2006; Matthews et al., 2007; Shi et al., 2006; Sims et al., 2005 Sims et al., , 2007 Vermeulen et al., 2007 Vermeulen et al., , 2010 Wysocka et al., 2006) . Various repressor proteins have been found to bind unmodified H3K4, including BHC80 (component of CoREST), DNMT3L (in complex with DNA de novo methyltransferase DNMT3A and DNMT3B), and UHRF1 (in complex with the DNA maintenance methyltransferase DNMT1) (Lan et al., 2007; Nady et al., 2011; Ooi et al., 2007) . H3K4me3 interferes with the binding of these repressors and thus may be involved in inhibition of DNA methylation. In addition, H3K4me3 was recently shown to keep DNMT3A in an autoinhibitory state and removal of histone methylation leads to enzymatic activation of DNMT3A (Guo et al., 2015) . Therefore, H3K4me3 may recruit or repel a specific set of downstream effectors from enhancers near PGC determinant genes for transcriptional activation during differentiation.
Our results demonstrate that Mll2/COMPASS is required for the steady-state expression of several different genes during (legend continued on next page) differentiation including genes involved in PGC specification during development. Removal of H3K4me3 from bivalent chromatin by Mll2 depletion in mESC skews cells toward differentiation and leads to prominent defects during development (Glaser et al., 2006; Lubitz et al., 2007) . As seen in the pluripotent ES cells, PGCs also maintain a bivalent domain at promoters of key regulators of all three germ layers (Lesch and Page, 2014) . We propose that Mll2 is not only required for the establishment of PGCs during differentiation through H3K4 methylation of key PGC genes but it may also be essential for maintaining the bivalent chromatin state for normal PGC function.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines HEK293 cells and mouse embryonic fibroblasts (MEF) were maintained in DMEM plus 10% FBS. Mouse V6.5 embryonic stem cells were cultured in 0.1% gelatin-coated tissue culture flasks with irradiated MEF feeder cells. Cells were grown in DMEM supplemented with 15% FBS (HyClone), 2 mM L-glutamine, 0.1 mM nonessential amino acids (StemCell Technologies) and 1,000 U/ml recombinant LIF (Millipore, ESG1107).
Expression Plasmids and short hairpin RNAs
Human full-length MLL2 cDNA was subcloned into pFN205K EF1a plasmid with an amino-terminal Halo tag between Sgf I and Pme I sites. Halo-tagged MLL2 (DCXXC) and MLL2 (Y2604A) plasmids were generated by deleting amino acids from 958 to 1000 of the CXXC domain or replacing tyrosine 2604 within the SET domain, respectively (Dillon et al., 2005) . Plasmids and shRNA sequences are provided in the Key Resources Table. Table) were cloned into the pLKO.1 vector (Addgene). Mouse V6.5 ES cells were infected with lentiviruses expressing shRNAs for 24 hr before selection with 2 mg/ml puromycin for 2 d. For ChIP-seq and RNA-seq experiments, cells were grown for one passage without feeder cells for 30 min before harvesting.
METHOD DETAILS
Antibody Generation Histone H3K4me1, H3K4me2, H3K4me3 were generated in our lab and have been used and described in our previous studies (Hu et al., 2013a; Hu et al., 2013b) . Carboxyl-terminal antibodies to human MLL2 were made as follows: CT1 refers to rabbits #9172 and #9173 and were generated with the MLL2 peptide spanning amino acids 2071-2220; CT2 refers to rabbit #9175 and was generated with the MLL2 peptide spanning amino acids 2264-2413. The peptides were expressed as His-tag fusion proteins in pET-16b vector and purified on NTA-agarose according to QIAGEN's protocol.
Lentivirus-based Knockdowns, Rescue Experiments and Generation of Embryoid Bodies
Lentivirus-mediated knockdown has been described previously (Hu et al., 2013b) . The hanging drop method was used to form embryoid bodies (EBs) by culturing 1000 mouse ES cells in 25 ml differentiation medium (without LIF) on the lid of 150 mm culture dish for the indicated number of days. For generation of human MLL2-rescue mouse ES cells, constructs were linearized with Mlu I restriction enzyme and electroporated into wild-type or Mll2 KO mouse ES cells with the Gene Pulser Xcell system (BioRad) with a setting of 250V, 500 mF capatitance. 24 hr post electroporation, cells were selected with 400 mg/ml G418 for 3 days followed by growing for one passage for 30 min to remove feeder cells before harvesting.
CRISPR-mediated Knockouts and Knockins sgRNAs were designed using the CRISPRtool (http://crispr.mit.edu) and cloned into PX459 vector (Addgene, 48139). Targeting vector and linearized donor vector were co-electroporated into V6.5 mouse embryonic stem cells and 24 hr later followed by 2 days of puromycin selection. For generation of CXXC and catalytically deficient mutants of endogenous Mll2, cells were continued to be selected in the presence of neomycin drug for a week. Targeted single-ES cell colonies were screened by PCR with primers (see Figure 4A and 4B) and analyzed by agarose-gel electrophoresis. PCR products were sequenced to further validate the genomic editing.
PGCLC Induction
PGCLCs induction was conducted following a previously described protocol (Hayashi et al., 2011; Hayashi and Saitou, 2013) . Briefly, mouse ES cells cultured in N2B27 medium (N-2: ThermoFisher Scientific, 17502-048; B27: ThermoFisher, 12587-010) plus LIF and 2i (1mM MEK inhibitor, Stemgent, PD0325901; 3mM GSK-3b inhibitor, Stemgent, CHIR99021) were trypsinized and 1 3 10 5 cells were seeded into one well of 12-well plate pre-coated with 5ug/ml plasma fibronectin (Millipore, FC010). After two days of differentiation in N2B27 medium supplemented with 1% knockout serum replacement (KSR, ThermoFisher, 10828-028), 20 ng/ml activin A (Peprotech, cat, and 12 ng/ml bFGF (ThermoFisher, 13256-029), the resulting EpiLCs were trypsinized and 2 3 10 4 cells were plated into one well of 96-well low cell-binding plate (Sigma, Z721093) for 4 days of differentiation into PGCLCs in serum-free GMEM (ThermoFisher, 11710-035) medium supplemented with 15% KSR, 1 3 NEAA (ThermoFisher,11140-050), 1 3 L-glutamine (ThermoFisher, 25030081), 1 3 sodium pyruvate (ThermoFisher, 1360070), 1 3 penicillin-streptomycin (ThermoFisher, 15140122), 55 nM 2-Mercaptoethanol (ThermoFisher, 21985023), 1,000 U of LIF, 500 ng/ml BMP4 (R&D, 314-BP-010), 500 ng/ml BMP8a (R&D, 1073-BP-010), 100 ng/ml SCF (R&D, 455-MC-010) and 50 ng/ml EGF (R&D, 2028-EG-200) . At the end of day 4 of differentiation, PGCLCs aggregates were either harvested for RNA extraction or dissociated for flow cytometric analysis.
FACS Analysis
For quantification of PGCLCs, differentiated aggregates were trypsinized at 37 C for 8 min and quenched with MEF medium. The dissociated cells were washed two times in FACS buffer (PBS with 0.1% BSA) and stained with PE-conjugated anti-mouse/rat CD61 (BioLegend, 104308, 1:200 dilutions) and anti-human/mouse SSEA1 eFluorÒ660 (eBioscience, 1:200 dilutions) antibodies for 1 hr on ice followed by three washes with FACS buffer. Stained cells were fixed in 4% paraformaldehyde for 30 min on ice and washed with FACS buffer for three times before analysis was performed with a FACSCantoll cytometer (BD Bioscience).
Immunoprecipitation
Immunoprecipitations were performed as previously described (Hu et al., 2013c) . Briefly, V6.5 mouse ES cells were lysed in RIPA (20 mM Tris-Hcl [pH 7.4], 150 mM NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol [DTT] ) and protease inhibitors (Sigma). Cleared lysates were incubated with the indicated antibodies and protein A/G PLUS agarose (Santa Cruz, sc-2003) . After washing beads, immunoprecipitates were eluted with loading buffer for SDS-PAGE. FDR < 0.05. Enrichment for H3K27me3 was determined with the broad domain peak detector SICER v1.1 (Zang et al., 2009 ) at the FDR < 1e-8, window size of 200, and gap size of 600.
Non-promoter peaks are the peaks that reside at least 1kb away from a transcription start site (TSS), with the remaining peaks being the TSS peaks. Gene annotations and TSS information were from Ensembl 67. Peaks were assigned to the features of its nearest gene. Co-bound peaks were called if the peak regions of two samples overlap. The significance of peak overlap was tested by GAT .
Replicate Information
Mll2 ChIP-seq with two independent antibodies were analyzed separately to gain comprehensive information on its genome-wide distribution and to increase our confidence in the specificity of two antibodies. The overlapping high-confidence peak regions of two biological replicates of H3K4me3 were used for further analysis. The overlapping peaks were merged into one region as the union of all. One replicate is generated from this study, the other is from GEO: GSE48172.
ChIP-seq Heatmaps and Enrichment Profiles
For ChIP-seq heatmaps, regions of interest were depicted at the center of each peak or nearest TSS and sorted by occupancy. Regions spanning 5 kb on either side of the indicated feature were binned into 25 bp windows. Coverage is normalized into reads per million (RPM). Occupancies were calculated as the mean coverage under each peak region. P values for boxplots were determined with the Wilcoxon rank sum test. For ChIP-Seq enrichment profiles, regions of interest were shown for each factor as a binary value of enriched/not enriched. The regions were centered at the center of each peak and sorted by the shortest distance of peak center to an annotated TSS. Regions shown are oriented 5 0 to 3 0 corresponding to the orientation of the nearest gene. Regions spanning 50 kb on either side of feature indicated were binned into 200 bp windows. Each line represents a peak and its surrounding region.
RNA-Seq Analysis
Sequencing reads were aligned to the mouse genome UCSC mm9 (see Table S1 for alignment statistics) and to gene annotations from Ensembl 67 using TopHat v2.0.13 ), using option -g 1 -x 1. R package edgeR 3.0.8 was used to perform differential expression analysis at FDR < 1e-3 (Robinson et al., 2010) . To estimate sample dispersion better, all the RNaseq samples are combined to fit one generalized linear model. Genes that expressed (> = 1 RPM) in less than 2 samples are filtered out. External sequencing data was downloaded from GEO48172 as raw reads and aligned in the same way as internally sequenced samples. Gene Ontology (GO) analysis of differentially expressed genes in Mll2 KO mouse ES cells was performed by Metascape . MA plots are generated by edgeR: A is logCPM, M is logFC. x axis indicates averaged expression level (log2 normalized counts). y axis represents log2 fold changes of normalized counts of Mll2 knockout (KO) cells versus the parental cells.
4C-Seq Analysis
Reads were demultiplexed by allowing no mismatches in the library index and 1 mismatch in viewpoint sequences. The library indexes were trimmed before mapping. 4cseqpipe was used for alignment, normalization and generating near-cis domainograms (van de Werken et al., 2012b) .
Data Sources
Data generated for this study includes ChIP-seq data for H3K4me3, MLL2, shMll2_MLL2, H3K4me3 in Mll2WT_Vec, Mll2KO_Vec, Mll2KO_MLL2WT, Mll2KO_MLL2(DCXXC) and Mll2_MLL2(Y2604A) ES cells, H3K9ac, H3K27ac and Pol II in ES cells, and H3K4me3 in MEF cells. Other datasets come from previously published studies. Replicates for H3K4me3, shMLL2_H3K4me3 and RNA-seq in ES cells are from GEO: GSE48172. p300, H3K4me1 and H3K27ac ChIP-seq data are from GEO: GSE24164 (Creyghton et al., 2010) . H3K27me3 ChIP-seq data are from GEO: GSE12241 (Mikkelsen et al., 2007) . H3K4me3 ChIP-seq in Cxxc1 (Cfp1) WT and KO ES cells are from ArrayExpress repository under accession E-ERAD-79 (Reynolds et al., 2012) . CpG islands were downloaded from UCSC browser mm9.
DATA AND SOFTWARE AVAILABILITY
ChIP-seq and RNA-seq datasets have been deposited at GEO: GSE78708.
